KRIBIOLISA™ Infliximab (REMICADE) ELISA

Enzyme Immunoassay for the Quantitative Determination of Infliximab in serum, plasma and cell culture supernatant. Infliximab is a monoclonal antibody which has high specificity for TNFα, and does not neutralize TNF beta. Infliximab causes programmed cell death of TNFα-expressing activated T lymphocytes, an important cell type mediating inflammation; hence it is generally assumed that resolution of activated T cells by Infliximab explains its efficacy in Crohn's disease. Krishgen PK kits, developed using the innovator drug as calibrator, are used for the quantitation of serum protein drug levels, and can be used for biosimilar and generics research as well. About the kit: - Uses anti-idiotypic antibodies sourced from our vendor partner in the US, which ensures higher specificity, and low cross reactivity. - Recovery rates are between 85 - 115% - Ready to use with a standard protocol with break-apart pre-coated wells - Validated as per US FDA guidelines for Bioassays - Optimized for matrix effects to ensure higher sensitivity. - Shelf life: 1 year The method employs the quantitative sandwich enzyme immunoassay technique. Antibodies to Infliximab arepre-coated onto microwells. Samples and standards are pipetted into microwells and human Infliximab present in the sample are bound by the capture antibody. Then, a HRP (horseradish peroxidase) conjugated anti-Infliximab antibody is pipetted and incubated. After washing microwells in order to remove any non-specific binding, the ready to use substrate solution (TMB) is added to microwells and color develops proportionally to the amount of Infliximab in the sample. Color development is then stopped by addition of stop solution. Absorbance is measured at 450 nm.